1. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. 2. patient has a do-not-resuscitate (dnr) or do-not-intubate (dni) order in place 3. patient has severe chronic obstructive pulmonary disease (copd), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.). 4. patient is on chronic immunosuppressive medication. 5. as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study. 6. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (n-acetyltryptophan, sodium caprylate). 7. patient has known pregnancy or is currently breastfeeding. 8. participation in another clinical trial (not including treatments for covid-19 as approved by the fda through expanded access or compassionate use). 9. baseline qt prolongation.

1. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. 2. patient has a do-not-resuscitate (dnr) or do-not-intubate (dni) order in place 3. patient has severe chronic obstructive pulmonary disease (copd), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.). 4. patient is on chronic immunosuppressive medication. 5. as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study. 6. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (n-acetyltryptophan, sodium caprylate). 7. patient has known pregnancy or is currently breastfeeding. 8. participation in another clinical trial (not including treatments for covid-19 as approved by the fda through expanded access or compassionate use). 9. baseline qt prolongation.

in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. patient has a do-not-resuscitate (dnr) or do-not-intubate (dni) order in place patient has severe chronic obstructive pulmonary disease (copd), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.). patient is on chronic immunosuppressive medication. as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (n-acetyltryptophan, sodium caprylate). patient has known pregnancy or is currently breastfeeding. participation in another clinical trial (not including treatments for covid-19 as approved by the fda through expanded access or compassionate use). baseline qt prolongation.

in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. patient has a do-not-resuscitate (dnr) or do-not-intubate (dni) order in place patient has severe chronic obstructive pulmonary disease (copd), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.). patient is on chronic immunosuppressive medication. as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (n-acetyltryptophan, sodium caprylate). patient has known pregnancy or is currently breastfeeding. participation in another clinical trial (not including treatments for covid-19 as approved by the fda through expanded access or compassionate use). baseline qt prolongation.

1. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. 2. patient has a do-not-resuscitate (dnr) or do-not-intubate (dni) order in place 3. patient has severe chronic obstructive pulmonary disease (copd), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.). 4. patient is on chronic immunosuppressive medication. 5. as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study. 6. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (n-acetyltryptophan, sodium caprylate). 7. patient has known pregnancy or is currently breastfeeding. 8. participation in another clinical trial (not including treatments for covid-19 as approved by the fda through expanded access or compassionate use). 9. baseline qt prolongation.

1. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. 2. patient has a do-not-resuscitate (dnr) or do-not-intubate (dni) order in place 3. patient has severe chronic obstructive pulmonary disease (copd), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.). 4. patient is on chronic immunosuppressive medication. 5. as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study. 6. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (n-acetyltryptophan, sodium caprylate). 7. patient has known pregnancy or is currently breastfeeding. 8. participation in another clinical trial (not including treatments for covid-19 as approved by the fda through expanded access or compassionate use). 9. baseline qt prolongation.